Leiner Naproxen Sales Decline Due To Recent Heart Risk Concerns
This article was originally published in The Tan Sheet
Executive Summary
Study data associating naproxen with a higher cardiac risk translated into a 30% decline in Leiner's fiscal third-quarter sales of the private label analgesic